Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT ID: NCT05979779
Last Updated: 2025-04-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
219 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-09-05
Study Completion Date
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ascending Dose Study of HU6 in Healthy Volunteers
NCT04463017
NASH - Nonalcoholic Steatohepatitis
COMPLETED
PHASE1
6-week Safety and PD Study in Adults With NAFLD
NCT03256526
Non-alcoholic Fatty Liver Disease
COMPLETED
PHASE2
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
NCT04767529
NASH - Nonalcoholic Steatohepatitis
COMPLETED
PHASE2
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
NCT03976401
NASH - Nonalcoholic Steatohepatitis
COMPLETED
PHASE2
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
NCT02912260
Non-alcoholic Steatohepatitis
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 (150 mg, 300 mg, and 450 mg) and placebo in approximately 204 subjects with NASH.
Subjects will be screened over a 49-day period to determine their eligibility based on specific history, physical, laboratory, and imaging evaluations, which will require more than one visit during the screening period. On Day 1, subjects will be randomized 2:1:2:2 into 1 of 4 treatment groups (placebo, 150 mg HU6, 300 mg HU6, or 450 mg HU6). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, PD, and PK during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Subjects will be screened over a 49-day period to determine their eligibility based on specific history, physical, laboratory, and imaging evaluations, which will require more than one visit during the screening period. On Day 1, subjects will be randomized 2:1:2:2 into 1 of 4 treatment groups (placebo, 150 mg HU6, 300 mg HU6, or 450 mg HU6). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, PD, and PK during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Fatty Liver
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a Phase 2, randomized, parallel-group, placebo-controlled, double-blind study where subjects will be randomized to one of 3 HU6 dose levels or placebo.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Treatment: HU6 Planned doses of HU6
Group Type
EXPERIMENTAL
HU6
Intervention Type
DRUG
HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
Placebo Comparator Non-active study drug
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HU6
HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
Intervention Type
DRUG
Placebo
Placebo
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Able to understand the procedures and requirements of the study and provide written informed consent and authorization for protected health information disclosure.
2. Willing and able to comply with the requirements of the study protocol.
3. Male or female ≥18 years of age at time of informed consent.
4. Subject has a screening Fibroscan® CAP score \>306 decibels per meter (dB/m) and interquartile range to median ratio (IQR/Med) \<30%.
5. Subject has ≥8% liver fat determined by screening Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).
6. Subject has moderate to advanced liver fibrosis based on documented history of biopsy score of F2 or F3 within 12 months prior to Screening, or subject has a screening Fibroscan® vibration-controlled transient elastography (VCTE) score ≥ 7.0 to ≤ 15.0 kPa.
7. Body mass index (BMI) ≥27.0 kg/m2.
8. Clinically euthyroid as assessed by a thyroid profile utilizing TSH and T4 testing at screening as assessed by the investigator based on the medical history of the subject.
9. Subjects with a diagnosis of glaucoma must be controlled and stable (no changes in treatment regimen within 3 months prior to Screening).
10. Inclusion as per investigator assessment of general medical status and as documented by medical history, physical examination, vital sign assessments, 12-lead ECG, clinical laboratory assessments, and general observations.
2. Willing and able to comply with the requirements of the study protocol.
3. Male or female ≥18 years of age at time of informed consent.
4. Subject has a screening Fibroscan® CAP score \>306 decibels per meter (dB/m) and interquartile range to median ratio (IQR/Med) \<30%.
5. Subject has ≥8% liver fat determined by screening Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).
6. Subject has moderate to advanced liver fibrosis based on documented history of biopsy score of F2 or F3 within 12 months prior to Screening, or subject has a screening Fibroscan® vibration-controlled transient elastography (VCTE) score ≥ 7.0 to ≤ 15.0 kPa.
7. Body mass index (BMI) ≥27.0 kg/m2.
8. Clinically euthyroid as assessed by a thyroid profile utilizing TSH and T4 testing at screening as assessed by the investigator based on the medical history of the subject.
9. Subjects with a diagnosis of glaucoma must be controlled and stable (no changes in treatment regimen within 3 months prior to Screening).
10. Inclusion as per investigator assessment of general medical status and as documented by medical history, physical examination, vital sign assessments, 12-lead ECG, clinical laboratory assessments, and general observations.
Exclusion Criteria
Subjects will be excluded from the study if any of the following criteria are met:
1. The subject has a history of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
2. The subject has a history of acute pancreatitis within 1 year of Screening or chronic pancreatitis of any cause.
3. History of any bariatric surgery intervention, including but not limited to lap banding, intragastric balloon, duodenal-jejunal sleeve, or bariatric surgery or plans for bariatric surgery prior to conclusion of study participation.
4. Have obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome, polycystic ovarian syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
5. Any surgical or medical condition or history that, in the opinion of the investigator in consultation with the medical monitor, may potentially alter the absorption, metabolism, or excretion of study treatment.
6. History of or treatment for clinically significant gastroparesis, inflammatory bowel disease, or any surgery of the upper gastrointestinal tract with the exception of cholecystectomy, or minor gastric procedures that are approved by the medical monitor.
7. History (including any family history) of malignant hyperthermia.
8. History of chronic serious recurrent skin rashes of unknown cause.
9. History of malignancy within 5 years (except cutaneous basal or squamous cell carcinoma, carcinoma-in-situ, or low-grade prostate cancer).
10. History of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.
11. NYHA Functional Class II, III, or IV heart failure.
12. Subject has a pacemaker.
13. Active kidney disease requiring therapy, kidney transplant, or eGFR \<45 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation.
14. Significant and unstable lung disease (chronic obstructive pulmonary disease \[COPD\], emphysema, pulmonary fibrosis, or asthma) requiring oxygen or chronic daily medication. Note that mild, stable COPD and asthma on inhalers are allowed.
15. Subject has a diagnosed history of obstructive sleep apnea or uses continuous positive airway pressure (CPAP).
16. Subject has a history of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to Screening.
17. Subject has any history of agranulocytosis.
18. Subject has Wilson's disease.
19. Familial (mother/father/sibling) and/or personal history of retinal detachment any time in the past.
20. Subject has history of prior vitrectomy due to prior retinal condition.
21. Subject has a contraindication to dilation for ophthalmologic examination.
22. Evidence of the following on screening ophthalmologic examination:
1. Peripheral retinal pathology, retinal tears, lattice, or nondiabetic ocular condition that requires treatment or intervention within 3 months of Screening.
2. Diabetic retinopathy with macular exudates or macular edema (evidence of microaneurysms is not an exclusion).
3. Any active macular disease that affects the vision, including macular pucker (epiretinal membrane), retinal vein occlusion, and macular degeneration.
4. Subjects with significant visual impairment due to lens opacity from cataracts such that surgery will be required within the duration of the study in the opinion of the consulting ophthalmologist. (Subjects with cataract surgery \>3 months prior to Screening may be included.)
5. Subject has substantial media opacities that preclude successful retinal imaging.
23. Any condition (e.g., ongoing substance, drug, or alcohol abuse) that may interfere with participation or safety of investigations, in the opinion of the Investigator.
24. A history of moderate alcohol consumption defined as drinking ≥ 2 drinks per day for men or ≥ 1 drink per day for women. (A drink is defined as 12 ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits.).
25. Subjects with untreated, uncontrolled, or unstable hypertension (systolic blood pressure \[SBP\] \>160 and/or diastolic blood pressure \[DBP\] \>100 mmHg upon repeat evaluation at screening). If subject is treated with antihypertensive medication, the regimen must be stable at least 1 month prior to screening.
26. Subjects with untreated or persistent hypotension (SBP \<90 mmHg) or symptomatic hypotension (that, in the opinion of the Investigator, requires active treatment).
27. Tachycardia (\>100 beats/minute) at screening.
28. QTcF \> 450 msec at screening for males and QTcF \> 470 msec at screening for females.
29. Use of any of the following medications:
1. The following oral antidiabetic drugs are prohibited within 3 months prior to screening and continuing throughout the study: insulin, meglitinides, thiazolidinediones, glucagon-like peptide (GLP-1) agonists, and gastric inhibitory polypeptide (GIP)/GLP-1 agonists.
2. The following are prohibited within 3 months prior to screening (or planned use during the study) when used for weight loss: herbal preparation, over the counter (OTC) drug, mail order or prescription drug.
3. Prescription or OTC stimulants including: dextroamphetamine/Dexedrine, dextroamphetamine/amphetamine combination product/Adderall, or methylphenidate (Ritalin®, Concerta®).
4. Recent (within 3 months of screening) or current use of obeticholic acid/Ocaliva, systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines.
5. Warfarin, heparin, factor Xa inhibitors (e.g., dabigatran, betrixaban, edoxaban, apixaban, and rivaroxaban).
6. Vitamin E: use of ursodiol or high-dose vitamin E (\>400 IU/day) for at least 1 month within the previous 6 months or started high dose vitamin E within the previous 3 months of Screening.
7. Drugs with high risk of idiosyncratic drug-induced neutropenia (IDIN) or agranulocytosis (Andres 2018, Curtis 2017): antithyroid drugs (propylthiouracil and methimazole), ticlopidine, clozapine, phenothiazines, sulfasalazine, vancomycin, amoxicillin, ceftriaxone, ciprofloxacin, cotrimaxozole, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole (Bactrim® or Septra®).
8. Concomitant medications that prolong the QT/QTc interval and are known to be associated with increased risk of Torsade des pointes as identified in the https://crediblemeds.org/ website list category of 'Known Risk.'
30. Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD)/NASH, or any of the following, as determined by the central laboratory during screening:
1. International normalized ratio (INR) ≥1.3, or
2. ALT \>5.0× the ULN for the reference range, or
3. AST \>5.0× the ULN for the reference range, or
4. Alkaline phosphatase (ALP) \>2.0× the ULN for the reference range, or
5. Total bilirubin \>1.2× the ULN for the reference range (except for cases of known Gilbert's Syndrome).
31. Laboratory Values at Screening:
1. Hemoglobin \<9.5 g/dL, or
2. ANC ≤1500/μL, or
3. Marked hypertriglyceridemia (\>1000 mg/dL), or
4. Copper \<LLN for the reference range, or
5. Ceruloplasmin \<LLN for the reference range, or
6. Serologic evidence of hepatitis B based on hepatitis B surface antigen (HBsAG), or
7. Serologic evidence of hepatitis C antibody (HCV Ab) and HCV RNA, or
8. Serologic evidence of human immunodeficiency virus (HIV).
9. Hemoglobin A1c (HbA1c) \> 9.5%.
32. Intolerance to MRI or with conditions contraindicated for MRI procedures including but not limited to:
1. Having surgical clips/metallic implants/shrapnel -or-
2. Claustrophobia, have a history of claustrophobia, or intolerance of closed or small spaces.
33. Participation in another clinical trial at the time of screening or exposure to any investigational agent, including topical agents, within 30 days or 5 half-lives prior to Day 1, whichever is longer.
34. For subjects with a recent active viral, bacterial, or parasitic infection, they must have discontinued any treatment for their infection at least 5 days prior to screening. Patients who test positive for COVID-19 during the screening period must have a negative rapid antigen test prior to randomization.
1. The subject has a history of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
2. The subject has a history of acute pancreatitis within 1 year of Screening or chronic pancreatitis of any cause.
3. History of any bariatric surgery intervention, including but not limited to lap banding, intragastric balloon, duodenal-jejunal sleeve, or bariatric surgery or plans for bariatric surgery prior to conclusion of study participation.
4. Have obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome, polycystic ovarian syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
5. Any surgical or medical condition or history that, in the opinion of the investigator in consultation with the medical monitor, may potentially alter the absorption, metabolism, or excretion of study treatment.
6. History of or treatment for clinically significant gastroparesis, inflammatory bowel disease, or any surgery of the upper gastrointestinal tract with the exception of cholecystectomy, or minor gastric procedures that are approved by the medical monitor.
7. History (including any family history) of malignant hyperthermia.
8. History of chronic serious recurrent skin rashes of unknown cause.
9. History of malignancy within 5 years (except cutaneous basal or squamous cell carcinoma, carcinoma-in-situ, or low-grade prostate cancer).
10. History of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.
11. NYHA Functional Class II, III, or IV heart failure.
12. Subject has a pacemaker.
13. Active kidney disease requiring therapy, kidney transplant, or eGFR \<45 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation.
14. Significant and unstable lung disease (chronic obstructive pulmonary disease \[COPD\], emphysema, pulmonary fibrosis, or asthma) requiring oxygen or chronic daily medication. Note that mild, stable COPD and asthma on inhalers are allowed.
15. Subject has a diagnosed history of obstructive sleep apnea or uses continuous positive airway pressure (CPAP).
16. Subject has a history of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to Screening.
17. Subject has any history of agranulocytosis.
18. Subject has Wilson's disease.
19. Familial (mother/father/sibling) and/or personal history of retinal detachment any time in the past.
20. Subject has history of prior vitrectomy due to prior retinal condition.
21. Subject has a contraindication to dilation for ophthalmologic examination.
22. Evidence of the following on screening ophthalmologic examination:
1. Peripheral retinal pathology, retinal tears, lattice, or nondiabetic ocular condition that requires treatment or intervention within 3 months of Screening.
2. Diabetic retinopathy with macular exudates or macular edema (evidence of microaneurysms is not an exclusion).
3. Any active macular disease that affects the vision, including macular pucker (epiretinal membrane), retinal vein occlusion, and macular degeneration.
4. Subjects with significant visual impairment due to lens opacity from cataracts such that surgery will be required within the duration of the study in the opinion of the consulting ophthalmologist. (Subjects with cataract surgery \>3 months prior to Screening may be included.)
5. Subject has substantial media opacities that preclude successful retinal imaging.
23. Any condition (e.g., ongoing substance, drug, or alcohol abuse) that may interfere with participation or safety of investigations, in the opinion of the Investigator.
24. A history of moderate alcohol consumption defined as drinking ≥ 2 drinks per day for men or ≥ 1 drink per day for women. (A drink is defined as 12 ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits.).
25. Subjects with untreated, uncontrolled, or unstable hypertension (systolic blood pressure \[SBP\] \>160 and/or diastolic blood pressure \[DBP\] \>100 mmHg upon repeat evaluation at screening). If subject is treated with antihypertensive medication, the regimen must be stable at least 1 month prior to screening.
26. Subjects with untreated or persistent hypotension (SBP \<90 mmHg) or symptomatic hypotension (that, in the opinion of the Investigator, requires active treatment).
27. Tachycardia (\>100 beats/minute) at screening.
28. QTcF \> 450 msec at screening for males and QTcF \> 470 msec at screening for females.
29. Use of any of the following medications:
1. The following oral antidiabetic drugs are prohibited within 3 months prior to screening and continuing throughout the study: insulin, meglitinides, thiazolidinediones, glucagon-like peptide (GLP-1) agonists, and gastric inhibitory polypeptide (GIP)/GLP-1 agonists.
2. The following are prohibited within 3 months prior to screening (or planned use during the study) when used for weight loss: herbal preparation, over the counter (OTC) drug, mail order or prescription drug.
3. Prescription or OTC stimulants including: dextroamphetamine/Dexedrine, dextroamphetamine/amphetamine combination product/Adderall, or methylphenidate (Ritalin®, Concerta®).
4. Recent (within 3 months of screening) or current use of obeticholic acid/Ocaliva, systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines.
5. Warfarin, heparin, factor Xa inhibitors (e.g., dabigatran, betrixaban, edoxaban, apixaban, and rivaroxaban).
6. Vitamin E: use of ursodiol or high-dose vitamin E (\>400 IU/day) for at least 1 month within the previous 6 months or started high dose vitamin E within the previous 3 months of Screening.
7. Drugs with high risk of idiosyncratic drug-induced neutropenia (IDIN) or agranulocytosis (Andres 2018, Curtis 2017): antithyroid drugs (propylthiouracil and methimazole), ticlopidine, clozapine, phenothiazines, sulfasalazine, vancomycin, amoxicillin, ceftriaxone, ciprofloxacin, cotrimaxozole, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole (Bactrim® or Septra®).
8. Concomitant medications that prolong the QT/QTc interval and are known to be associated with increased risk of Torsade des pointes as identified in the https://crediblemeds.org/ website list category of 'Known Risk.'
30. Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD)/NASH, or any of the following, as determined by the central laboratory during screening:
1. International normalized ratio (INR) ≥1.3, or
2. ALT \>5.0× the ULN for the reference range, or
3. AST \>5.0× the ULN for the reference range, or
4. Alkaline phosphatase (ALP) \>2.0× the ULN for the reference range, or
5. Total bilirubin \>1.2× the ULN for the reference range (except for cases of known Gilbert's Syndrome).
31. Laboratory Values at Screening:
1. Hemoglobin \<9.5 g/dL, or
2. ANC ≤1500/μL, or
3. Marked hypertriglyceridemia (\>1000 mg/dL), or
4. Copper \<LLN for the reference range, or
5. Ceruloplasmin \<LLN for the reference range, or
6. Serologic evidence of hepatitis B based on hepatitis B surface antigen (HBsAG), or
7. Serologic evidence of hepatitis C antibody (HCV Ab) and HCV RNA, or
8. Serologic evidence of human immunodeficiency virus (HIV).
9. Hemoglobin A1c (HbA1c) \> 9.5%.
32. Intolerance to MRI or with conditions contraindicated for MRI procedures including but not limited to:
1. Having surgical clips/metallic implants/shrapnel -or-
2. Claustrophobia, have a history of claustrophobia, or intolerance of closed or small spaces.
33. Participation in another clinical trial at the time of screening or exposure to any investigational agent, including topical agents, within 30 days or 5 half-lives prior to Day 1, whichever is longer.
34. For subjects with a recent active viral, bacterial, or parasitic infection, they must have discontinued any treatment for their infection at least 5 days prior to screening. Patients who test positive for COVID-19 during the screening period must have a negative rapid antigen test prior to randomization.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rivus Pharmaceuticals, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rob Schott, MD
Role: STUDY_DIRECTOR
Rivus Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ProSciento CRU
Chula Vista, California, United States
Site Status
Velocity Clinical Research
Los Angeles, California, United States
Site Status
Catalina Research Institute
Montclair, California, United States
Site Status
Northern California Research Center
Sacramento, California, United States
Site Status
Metro Clinical Trials
San Bernardino, California, United States
Site Status
Synergy Healthcare
Bradenton, Florida, United States
Site Status
ABMED Clinical Research Corp.
Cape Coral, Florida, United States
Site Status
Southwest General Healthcare Center
Fort Myers, Florida, United States
Site Status
Miami Clinical Research
Miami, Florida, United States
Site Status
Advanced Clinical Research
Miami, Florida, United States
Site Status
Century Research, LLC
Miami, Florida, United States
Site Status
Entrust Clinical Research
Miami, Florida, United States
Site Status
Panax Clinical Research
Miami Lakes, Florida, United States
Site Status
Tandem Clinical Research
Marrero, Louisiana, United States
Site Status
CenExel HRI
Berlin, New Jersey, United States
Site Status
Lillestol Research
Fargo, North Dakota, United States
Site Status
IMA Clinical Research-Austin
Austin, Texas, United States
Site Status
Mt Olympus Medical Research
Houston, Texas, United States
Site Status
Houston Research Institute
Houston, Texas, United States
Site Status
Texas Liver Institute
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIV-HU6-2202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175
COMPLETED
PHASE2
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
NCT03938246
COMPLETED
PHASE2
Phase 2a Study of HPG1860 in Subjects With NASH
NCT05338034
UNKNOWN
PHASE2
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
RECRUITING
PHASE3
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
ACTIVE_NOT_RECRUITING
PHASE3
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
COMPLETED
PHASE2
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
NCT05461105
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
NCT05402371
ACTIVE_NOT_RECRUITING
PHASE2
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
NCT05784779
UNKNOWN
PHASE1/PHASE2
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
NCT02217475
COMPLETED
PHASE2
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273
COMPLETED
PHASE2
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT04906421
COMPLETED
PHASE2
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
NCT04006145
COMPLETED
PHASE2
Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis
NCT00470171
COMPLETED
PHASE2
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT03676231
TERMINATED
PHASE2
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03248882
COMPLETED
PHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
NCT04171765
TERMINATED
PHASE2
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
NCT00590161
COMPLETED
PHASE2
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
NCT00267670
COMPLETED
PHASE2/PHASE3
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
NCT03656744
COMPLETED
PHASE2
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
NCT00740610
COMPLETED
PHASE2
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
NCT01277094
COMPLETED
PHASE1
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
NCT02927314
COMPLETED
PHASE2